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 Accumulation of noxious metabolites in the interstitial fluid
of brain may contribute to hepatic encephalopathy.
 Accumulation of such products may be due to reduced
glymphatic clearance mechanisms in the brain.
 We identified regions of impaired glymphatic clearance
function, which aligned closely with cognitive/behavioural
deficits.
 Reduced AQP4 expression was observed in the same regions.
 Altered AQP4 mediated glymphatic dysfunction may
contribute to pathogenesis of hepatic encephalopathy.Anna Hadjihambi, Ian F. Harrison,
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Lay summary
The ‘glymphatic system’ is a newly dis-
covered brain-wide pathway that facili-
tates clearance of various substances that
accumulate in the brain due to its activity.
This study evaluated whether the func-
tion of this system is altered in a model of
brain dysfunction that occurs in cirrhosis.
For the first time, we identified that the
clearance of substances from the brain in
cirrhosis is reduced because this clear-
ance system is defective. This study pro-
poses a new mechanism of brain
dysfunction in patients with cirrhosis
and provides new targets for therapy.Cirrhosis. This is an open access article under the CC BY-NC-ND
–49
t
p
t
a
y
f M
sc
l
M
la
m
l,
JOURNAL 
OF HEPATOLOGY
Research Article
CirrhosisImpaired brain glympha
hepatic ence
Anna Hadjihambi1,2,y, Ian F. Harrison3,y, Marta Cos
Rocío Gallego-Durán5, Svetlana Mastitskaya2, P
Nathan Davies1, Abeba Habtesion1, Mark F. L
1Liver Failure Group Institute for Liver and Digestive Health, Division o
NW3 2PF London, UK; 2Centre for Cardiovascular and Metabolic Neuro
London, WC1E 6BT London, UK; 3UCL Centre for Advanced Biomedica
London, UK; 4Ghent University, Department of Chemistry, Atomic and
281-S12, BE-9000 Ghent, Belgium; 5Institute of Biomedicine of Sevil
Sevilla, UCM Digestive Diseases & CIBERehd Sevilla, Spain; 6Depart
See Editoria
Background & Aims: Neuronal function is exquisitely sensitive
to alterations in the extracellular environment. In patients with
hepatic encephalopathy (HE), accumulation of metabolic waste
products and noxious substances in the interstitial fluid of the
brain is thought to result from liver disease and may contribute
to neuronal dysfunction and cognitive impairment. This study
was designed to test the hypothesis that the accumulation of
these substances, such as bile acids, may result from reduced
clearance from the brain.
Methods: In a rat model of chronic liver disease with minimal
HE (the bile duct ligation [BDL] model), we used emerging
dynamic contrast-enhanced MRI and mass-spectroscopy tech-
niques to assess the efficacy of the glymphatic system, which
facilitates clearance of solutes from the brain. Immunofluores-
cence of aquaporin-4 (AQP4) and behavioural experiments were
also performed.
Results:We identified discrete brain regions (olfactory bulb,
prefrontal cortex and hippocampus) of altered glymphatic clear-
ance in BDL rats, which aligned with cognitive/behavioural def-
icits. Reduced AQP4 expression was observed in the olfactory
bulb and prefrontal cortex in HE, which could contribute to
the pathophysiological mechanisms underlying the impairment
in glymphatic function in BDL rats.
Conclusions: This study provides the first experimental evi-
dence of impaired glymphatic flow in HE, potentially mediated
by decreased AQP4 expression in the affected regions.
Lay summary: The ‘glymphatic system’ is a newly discovered
brain-wide pathway that facilitates clearance of various sub-
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stances that accumulate in the brain due to its activity. This
study evaluated whether the function of this system is altered
in a model of brain dysfunction that occurs in cirrhosis. For
the first time, we identified that the clearance of substances
from the brain in cirrhosis is reduced because this clearance sys-
tem is defective. This study proposes a new mechanism of brain
dysfunction in patients with cirrhosis and provides new targets
for therapy.
 2018 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The mechanisms underlying the pathogenesis of hepatic
encephalopathy (HE) in patients with cirrhosis (chronic liver
disease) are not completely understood. Data available in the
literature suggest that noxious substances and metabolites such
as lactate, glutamate, bile acids and drugs accumulate in the
brain of patients with HE.1 The prevailing hypothesis proposes
that this occurs because of metabolic and transporter defects
induced by hyperammonaemia, inflammation and alterations
in blood brain barrier function.2,3
In the periphery, the lymphatic system is responsible for
interstitial fluid (ISF) clearance, a mechanism that is critical for
maintaining tissue homeostasis. Although neuronal function is
exquisitely sensitive to alterations in the extracellular environ-
ment, until recently, the brainwas believed to be devoid of a lym-
phatic drainage/clearance system. Recent studies identified a
brain-wide paravascular pathway that facilitates the efficient
clearance of various molecules, including toxic interstitial pro-
teins, lactate and other metabolites.4,5 Subarachnoid cere-
brospinal fluid (CSF) circulates through the brain parenchyma
along the paravascular spaces surrounding penetrating arteries,
exchanging with the surrounding ISF and facilitating the clear-
ance of interstitial solutes.4 ISF is then cleared along paravascular
spaces surrounding large calibre cerebral veins, which reach the
recently discovered meningeal lymphatic vessels6 and enter the019 vol. 70 j 40–49
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OF HEPATOLOGYsystemic circulation. This pathway has been termed the ‘‘glym-
phatic system” because of its apparent dependence on glial water
channels and its clearance function similar to that of the lym-
phatic system. That said, the precise definition of what consti-
tutes ‘‘glymphatic” function in the brain is still being debated
and discussed in the literature,7–9 and the precise role that glial
water channels play in such a clearance pathway is unclear. A
schematic describing this system in health and HE (according
to the findings of the current study) is depicted in Fig. 1.
In addition to clearing the brain, the glymphatic system is
thought to contribute to the distribution of growth factors, neu-
romodulators, carrier proteins and other solutes within the
brain.10 Failure of the glymphatic system (achieved either
experimentally11 or pathophysiologically12–15) may therefore
have critical adverse consequences, and has been linked to the
pathogenesis of neurodegenerative disease(s).5,16
In this study, we tested the hypothesis that the glymphatic
clearance mechanisms are impaired in cirrhosis, potentially
contributing to the development of the neurochemical pheno-
type observed in HE. Making use of the bile duct ligation
(BDL) rat model of chronic liver disease with minimal HE, we
used mass-spectroscopy techniques as well as cisternal delivery
Healthy
Hepatic encephalopathy
Periarterial space Perivenous space
VeinArtery
Towards meningeal
lymphatic vessels
Interstitial solutes
CSF/ISF exchange
Para-arterial influx
Para-venous efflux
Astrocyte
AQP4 Neuron
Fig. 1. Schematic of proposed alterations in glymphatic function in
hepatic encephalopathy. In health, glymphatic inflow of CSF occurs parallel
to arterial flow along the periarterial space (between the basement mem-
brane of smooth muscle cells and pia mater), where the water component of
CSF crosses the astrocytic AQP4 channels polarised to astrocyte end-feet and
enters the brain parenchyma. Here, CSF exchanges with ISF, allowing
interstitial solutes to be cleared out of the parenchyma via astroglial
transporters or channels, or pass through the astrocytic end-feet clefts to
the perivenous space. Effluxed waste is then cleared out of the CSF pool via
absorption by the meningeal lymphatic system. In hepatic encephalopathy,
our data suggests that this brain-wide clearance system becomes dysfunc-
tional, possibly because of reduced vessel coverage and polarisation of AQP4,
leading to toxic accumulation of interstitial solutes in the parenchyma.
Arrows indicate direction of flow. AQP4, aquaporin-4; CSF, cerebrospinal
fluid; ISF, interstitial fluid. (This figure appears in colour on the web.)Journal of Hepatologyof an MRI contrast agent, and dynamic contrast-enhanced MRI
(used previously to define the function of the glymphatic
system in rodents4,13,17–21 and in humans22–26) to measure
the relative function of this system in the diseased (HE) and
healthy rat brain.
Materials and methods
Animal models
All the experiments were performed in accordance with
the Animals (Scientific Procedures) Act 1986 (ASPA) revised
according to the European Directive 2010/63/EU and the UK
Home Office (Scientific Procedures) Act (1986) with prior
project approval from UCL’s internal Animal Welfare and
Ethical Review Body. Male Sprague-Dawley rats (body weight
350–400 g) were obtained from a commercial supplier
(Charles Rivers Laboratories, Inc., Oxford), and transported to
UCL at least 14 days prior to experimentation. Rats were group
housed (3 per cage) in individually ventilated cages kept on a
12 h light-dark cycle (light 7 am-7 pm), with ad libitum access
to standard rat chow and water, and environment enrichment
in the form of chew sticks and cardboard tubes.
A total of 46 animals were used in this project in the different
sub-studies. BDL and sham surgeries were performed as
previously reported27 on 22 and 24 animals respectively
(Details on surgical protocol in the supplementary section).
Blood and brain tissue were collected under terminal isoflu-
rane anaesthesia. Plasma biochemistry was performed using a
Cobas Integra II system (Roche Diagnostics).
Dynamic contrast-enhanced MRI
Five sham-operated and 5 BDL rats were anaesthetised, the dura
mater overlaying the cisterna magna was exposed and an
intrathecal 24-gauge infusion catheter (0.7  19 mm, B|Braun,
Melsungen, Germany) was advanced 1 mm into the cisternal
space. Following surgery, animals were transferred to an MRI
compatible cradle with a snout mask positioned to deliver
1.5% isoflurane in oxygen. Rats were maintained at 37 C core
body temperature and respiratory rate was maintained between
70 and 100 breaths per minute. All imaging was performed with
a 9.4 T VNMRS horizontal bore MR scanner (Agilent Inc., Santa
Clara, California, USA). A baseline scan was acquired prior to
intrathecal infusion of the paramagnetic contrast agent,
gadolinium (Gd-DTPA, 21 mM) via the pre-implanted catheter
(80 ll at 1.6 ll/min, total time 50 min). MR images were contin-
ually acquired throughout and after intrathecal infusion for a
total time of 144 min. At the end of the experiment the animal
was euthanised by sodium pentobarbital overdose (200 mg/kg).
Details on surgical protocol, image acquisition and processing
are available in the supplementary section.
Intracranial pressure measurements
In a separate group of BDL (n = 6) and sham-operated (n = 8)
animals, resting intracranial pressure (ICP) was determined.
Under general anaesthesia (5% isoflurane in oxygen for induc-
tion, 2% isoflurane in air for maintenance), the femoral artery
was cannulated for blood pressure measurements. The rats
were positioned in a stereotaxic frame with the head flexed to
50 and a midline incision was made at a midpoint between
the skull base and the occipital margin to the first vertebrae.
The underlying muscles were parted exposing the atlanto-
occipital membrane and dura mater overlaying the cisterna
magna. A 23-gauge needle attached to a cannula connected to2019 vol. 70 j 40–49 41
Research Article Cirrhosisa pressure transducer was inserted into the cisterna magna and
the system was sealed immediately using surgical glue. The ani-
mal was allowed to recover for 15 min and the ICP was
recorded. Data from previous studies have shown no significant
alterations in ICP during the chosen volume and rate of cisterna
magna contrast agent infusion.28
Microinjections of Gd-DTPA in the prefrontal cortex
evaluating brain tissue clearance
Under general anaesthesia (5% isoflurane in oxygen for induc-
tion, 2% isoflurane in air for maintenance) another 6 BDL and
6 sham-operated rats underwent a stereotaxic micro-infusion
of 4 ll Gd-DTPA (Magnevist 860 mM Gd-DTPA, MW 938 Da;
Schering Health Care Ltd. in water for injection) into the left
prefrontal cortex (anteroposterior, +2 mm, mediolateral,
+3 mm and dorsal to ventral, 1.75 mm, relative to bregma)
using a 10 ll glass Hamilton syringe (4 ll at 0.4 ll/min, total
time 10 min). After 30 min of the intracerebral infusion, the cis-
terna magna was exposed and was thoroughly cleaned with sal-
ine. A durotomy was made using a 23-gauge needle attached to
a 1 ml syringe, allowing CSF to be collected. At the end of the
experiment the animals were euthanised by overdose of sodium
pentobarbital (200 mg/kg, i.p). Blood was collected from the left
ventricle of the heart. The brain was also quickly removed from
the skull and dissected into the frontal (2.5 mm from bregma
forward), middle (2.5 to 10 mm from bregma), and the
hind brain (10 mm from bregma backwards). All samples
(blood plasma, CSF, brain tissue) were snap frozen in liquid
nitrogen and Gd-DTPA, as well as total tauro-conjugated bile
acids (in plasma and CSF), quantification was performed using
sector-field ICP-mass spectrometry (SF-ICP-MS) (details are
available in the supplementary section).AQP4 immunofluorescence and blood vessel labelling
Four BDL and 4 sham-operated animals were terminally anes-
thetised with urethane (1.9 g/kg i.p.) and transcardially per-
fused with ice-cold 0.9% sodium chloride solution followed by
4% paraformaldehyde (PFA) at 4 C. Brains were removed,
post-fixed in PFA overnight, and cryoprotected in 30% sucrose
for 48 h at 4 C. Coronal brain slices (30 lm) were sectioned
using a cryostat (Bright instruments, UK).
Olfactory bulb and prefrontal cortex sections were incubated
in blocking buffer for 2 h on a shaker, to minimise non-specific
binding of the antibody (10% goat serum in 0.1% Triton in PBS).
Tissue was then incubated in primary antibody aquaporin-4
(AQP4, 1:60, ab9512, Mouse monoclonal, Abcam) diluted in
blocking buffer for 24 h at 4 C on a shaker. Negative controls
were performed for each animal group by omitting the primary
antibody in one of the wells. Tissue was washed 3 times with
PBS for 10 min and subsequently incubated in the secondary
antibody, Alexa 568 anti-mouse (1:500, Molecular probes)
together with Alexa FluorTM 647 Conjugate Isolectin B4 (1:200,
Molecular Probes: I32450), diluted in the blocking buffer, for
24 h at 4 C on a shaker. Isolectin B4 binds to a-D-galactose resi-
dues in the basement membrane secreted by endothelial cells.29
After 3 final washes in PBS, the tissue was mounted on glass
slides and cover-slipped with Fluoroshields (Sigma). Slides were
then imaged using a Zeiss LSM 700 confocal microscope.
Quantification of AQP4 expression
Evaluation of the localisation of AQP4 to perivascular end-feet
and glial limitans was performed by measuring the pixel inten-
42 Journal of Hepatologysities of Isolectin and AQP4 immunoreactivity across cross sec-
tions of blood vessels in each brain region studied. For this,
fluorescent intensity for both Isolectin and AQP4 markers were
measured across a single 40 lm axis perpendicular to the vessel
orientation, and expressed as intensity, normalised to the inten-
sity of a randomly selected background region of interest (ROI)
in the same image for each antigen, to generate linear plots of
fluorescence extending from the brain tissue, into the vessel
and again into the surrounding brain tissue.
Quantification of AQP4 polarisation
Perivascular polarisation of AQP4 was measured as previously
described.10 Briefly, the median immunofluorescence intensity
of AQP4 immunopositivity in perivascular regions was mea-
sured. A threshold analysis was then used to measure the per-
centage of the region exhibiting AQP4 immunofluorescence
greater than or equal to perivascular AQP4 immunofluorescence
(AQP4% area). Polarisation was expressed as the percentage of
the region that exhibited lower AQP4 immunoreactivity than
the perivascular end-feet. AQP4 vessel coverage was measured
by firstly delineating the area of the vessel from the Isolectin
channel image. This ROI was then placed on the AQP4 channel
image thresholded for immunoreactivity, for extraction of the
percentage vessel coverage (% immunoreactivity of AQP4 of
whole delineated vessel).
Behavioural experiments
Spatial working memory, evaluating prefrontal cortex function,
in separate groups of sham-operated (n = 5) and BDL rats (n = 5)
was evaluated in the Barnes Maze. The training consisted of
1 day for habituation followed by the working memory training
which involved a paired sample task during the following 6 days
of training. Each daily session consisted of 2 identical trials (sam-
ple and retention). During both trials, the escape box was in a
fixed position every day, changing between days in a pseudoran-
dom order (details are available in the supplementary section).
To test the reference memory in the Barnes Maze and evalu-
ate hippocampal function, the escape box remained in the same
position during the training session for 5 days. Visual cues were
placed above the 4 quadrants of the maze and 4 trials were per-
formed per day for 5 days. Time spent to find the target hole
where the escape box used to be located (latency), distance
travelled, speed and path efficiency (1 indicates perfect
efficiency-animal moved in a straight line) were recorded and
analysed by ANY-maze software (Stoelting Co) (details are
available in the supplementary section).
Statistical analysis
Statistical comparisons between MR time course data and the
brain SF-ICP-MS data from sham-operated and BDL groups were
performed using 2-way ANOVA followed by Bonferroni post hoc
test. CSF and plasma SF-ICP-MS as well as ICP data from sham-
operated and BDL groups were compared using a Student’s t
test. Biochemistry data was analysed using one-way ANOVA.
Statistical comparisons between immunofluorescence line
profile data, area under the curve from line profile data and
AQP4 vessel coverage and polarisation from sham-operated
and BDL groups were performed using 2-way ANOVA followed
by Bonferroni post hoc test.
For the neurobehavioural experiments, statistical compar-
isons of data between sham-operated and BDL animals were
performed using 2-way ANOVA with Bonferroni post hoc test.
2019 vol. 70 j 40–49
For comparison of data within animal groups along training
days, 2-way ANOVA was applied followed by Tukey post hoc
test.
Statistical tests were performed using GraphPad Prism (v6
for Windows, San Diego, CA, USA), and all data were reported
as mean ± SEM. Differences with p value of <0.05 were consid-
ered significant. Sample sizes were calculated using Gpower
3 v3.1.9.2 (http://www.gpower.hhu.de/en.html)30 using a
‘means: ANOVA (two groups)’ test, with a desired power of
90% and a significance level of 5%. The effect size was calculated
from the difference in contrast infiltration observed in the olfac-
tory bulb of sham and BDL animals in a preliminary study
(n = 3). Based on this calculation, n = 5 was used. The same
calculations were performed for the other experiments when
possible, in order to determine appropriate n numbers.
For further details regarding the materials and methods used,
please refer to the CTAT table and supplementary information.
Results
Biochemistry
Plasma biochemistry, including ammonia concentration, was
assessed in all groups of animals (Table S1). Compared to sham
surgery, BDL resulted in a significant increase in plasma alanine
aminotransferase and bilirubin (p <0.001), indicating impaired
liver function, while albumin and total protein concentrations
were significantly decreased (p <0.001). Plasma ammonia con-
centration was significantly higher in BDL rats compared to
sham-operated animals (p <0.001). The level of total tauro-
conjugated bile acids was also significantly higher in both the
Glymphatic flow evaluated using dynamic contrast-
enhanced MRI
Dynamic contrast-enhanced MRI was used to visualise brain-
wide subarachnoid CSF-ISF exchange in anesthetised BDL and
sham-operated animals. The time course of parenchymal distri-
bution of the paramagnetic contrast agent, Gd-DTPA throughout
the brain was assessed as a measure of glymphatic flow.4,5 Fol-
lowing an intra-cisternal infusion of gadolinium, serial acquisi-
tion of T1-weighted MR images was performed (Fig. 2A). The
integrity of the skull was confirmed by monitoring the tempo-
ralis muscle for the presence of gadolinium (Fig. 3E), to ensure
a sealed and intact system, which is essential for the glymphatic
flow.
In order to assess the ability of the brain to distribute the
infused contrast agent, the brain was compartmentalised (on
analysis) and the quantification of signal intensity vs. time of
inflow was compared between BDL and sham-operated animals.
Parenchymal penetration of the contrast agent in the olfactory
bulb (p <0.0001) and prefrontal cortex (p = 0.01) was dramati-
cally reduced in BDL rats compared to sham-operated animals,
indicating that the efficacy of glymphatic flow in these areas
is compromised (Fig. 2C-D). In contrast, facilitated inflow of
contrast agent was observed in the hippocampus (p = 0.03) of
BDL rats (Fig. 2E), further suggesting that glymphatic flow is
altered in this HE model.
CSF filled compartments, including the aqueduct, third and
lateral ventricles, showed no significant differences in inflow
between sham-operated and BDL animals (Fig. 4A-D). Similarly,
time courses of the parenchymal distribution of the contrast
agent in the striatum (p = 0.4), midbrain (p = 0.7), caudal cortex
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Glymphatic clearance evaluated via Gd-DTPA quantification
using SF-ICP-MS
Following the assessment of glymphatic flow by MRI, a separate
cohort of animals was intracerebrally infused with Gd-DTPA,
the same imaging agent used for the MRI experiments. The
aim of these experiments evaluating the clearance of Gd-DTPA
from the brain was to validate the results of impaired glym-
phatic inflow that were observed using MRI.
Thirty minutes after the Gd-DTPA was infused in the pre-
frontal cortex, one of the most altered and accessible brain
regions according to the MRI results, blood plasma and CSF were
collected. Additionally, the brain was removed and dissected
into frontal (site of infusion), middle and hind brain regions.
The Gd-DTPA concentration in samples was then quantified
using SF-ICP-MS, revealing a trend towards less Gd-DTPA in cir-
culating plasma (p = 0.5) and CSF (p = 0.2) of BDL rats, however
these differences were not significant. However, these data sug-
images (Fig. 4D) and recorded ICP from the cisterna magna
(Fig. 2B), were then determined in sham-operated (n = 8) and
BDL (n = 6) animals. The results obtained demonstrated that
the observed contrast agent inflow and impaired clearance can-
not be attributed to altered pressure or volume differences in
the brain, as the volumes of brain regions (p > 0.05 for all
regions) and the ICP recorded from the cisterna magna
(p = 0.7) were not different between sham-operated and BDL
animals.
Evaluation of AQP4 expression and polarisation in the brain
regions of interest in sham-operated and BDL animals
The astrocytic water channel AQP4, which is highly polarised on
astrocytic end-feet, ensheathing brain vasculature, has been
shown to play an important role in the transport of CSF into
the brain parenchyma via the glymphatic system.5 It has also
been shown that with advancing age, glymphatic function is
reduced, possibly caused by astrocytic activation, associated
with altered AQP4 expression and localisation.10 In order to bet-
ter understand the underlying mechanism of impaired glym-
phatic function observed in animal models of HE, we
performed AQP4 immunofluorescence analysis and blood vessel
labelling with Isolectin in the two most affected brain regions;
the olfactory bulb and prefrontal cortex.
On the dual fluorescence images obtained, lines were drawn
across blood vessels and intensity measurements were made for
both AQP4 and Isolectin across vessel cross sections (Fig. S1).
Analysing the expression of AQP4 and Isolectin we observed
that, in the olfactory bulb, Isolectin and AQP4 intensities
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Research Article Cirrhosisgest that less Gd-DTPA had been cleared out of the brain of BDL
animals (Fig. 5A-B). In line with these data, significantly higher
Gd-DTPA content was recorded in the frontal brain tissue of BDL
compared to sham-operated rats (p <0.001), while the other
regions did not show significant differences in Gd-DTPA content
(Fig. 5C). This suggests that Gd-DTPA clearance from the pre-
frontal cortex is also impaired in BDL rats, similar to glymphatic
inflow in this region.
Measurement of intracranial pressure and volume of the
brain regions of interest in sham-operated and BDL animals
Impairment of parenchymal contrast agent penetration and
clearance could be due to altered ICP, or brain volume differ-
ences in BDL animals. Therefore, volumes of select brain regions,
obtained from 3D ROI measurements of contrast-enhanced MR
appeared similar between vessels from sham-operated and
BDL rats (Fig. 6A-B). While in the prefrontal cortex, Isolectin
appeared more intense in BDL rats, with a difference between
44 Journal of Hepatology 2019 vol. 70 j 40–49
150
100
50
0
0 30 60 90 120 150
Time (min)
p 
= 
0.
44
91
In
te
ns
ity
(%
 c
ha
ng
e 
fro
m
 b
as
el
in
e)
A B C
150
100
50
0
0 30 60 90 120 150
Time (min)
p 
= 
0.
35
10
In
te
ns
ity
(%
 c
ha
ng
e 
fro
m
 b
as
el
in
e)
Aqueduct Lateral ventricle
Fig. 4. Contrast agent inflow in CSF filled compartments (aqueduct, lateral v
altered in HE. Intensity (% change from baseline) vs. time plots of contrast agent
(n = 5) rats in the (A) aqueduct, (B) lateral ventricles and (C) 3rd ventricle. G
illustrating volume (mm3) of the brain regions of interest obtained from 3D ROI
animals, with no significant differences reported. Statistical comparisons were p
indicate the level of differences between the sham-operated and BDL groups. BD
region of interest.
A BPlasma CSF
* *
JOURNAL 
OF HEPATOLOGY2,000
1,500
1,000
500
0
Sham BDL
20,000
15,000
10,000
5,000
0
Sham BDL
[G
d]
 (μ
g/
L)
[G
d]
 (μ
g/
L)
p = 0.5
p = 0.2
p <0.001500
400
300
200
100
20 (μ
g/
L)
Sham
BDL
C BrainAQP4 intensities between groups (Fig. 6C-D). To simplify the
intensity measurements, we analysed the area under the curve
of the peaks and observed significantly lower AQP4 expression
compared to Isolectin in both the olfactory bulb (p <0.05) and
prefrontal cortex (p <0.01) of BDL rats, which was not the case
in sham-operated animals (Fig. 6E).
Furthermore, both AQP4 polarisation (degree to which AQP4
expression is polarised to blood vessels) and AQP4 vessel cover-
age (average% area of selected blood vessel which is covered by
AQP4) were measured. AQP4 polarisation (Fig. 7A, olfactory
bulb: p = 0.3; prefrontal cortex: p = 0.4) as well as vessel cover-
age (Fig. 7B, olfactory bulb: p = 0.1; prefrontal cortex: p = 0.1)
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Fig. 5. Impaired Gd-DTPA clearance in the prefrontal cortex, evaluated by
SF-ICP-MS in plasma, CSF and brain tissue of animals with HE. Summary
data illustrating Gd concentration in the (A) plasma, (B) CSF and (C) frontal,
middle and hind brain tissue of sham-operated (n = 6) and BDL (n = 6)
animals. Statistical comparisons for CSF and plasma samples were performed
using a Student’s t test while statistical comparisons of brain data were
performed using 2-way ANOVA followed by Bonferroni post hoc test. p values
indicate the level of differences between the sham-operated and BDL groups.
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Fig. 6. Altered AQP4 vs. Isolectin expression, in the olfactory bulb and
prefrontal cortex of animals with HE. (A-D) Plots of fluorescence signal
intensity vs. distance across blood vessels for AQP4 and Isolectin expression in
the olfactory bulb and prefrontal cortex of sham-operated (n = 4) and BDL rats
(n = 4). (E) Summary data indicating area under the curve of the peaks in the
intensity graphs, showing significantly lower AQP4 expression compared to
Isolectin in both the olfactory bulb and prefrontal cortex of BDL compared to
sham-operated animals. Statistical comparisons between immunofluores-
cence line profile data, and area under the curve were performed using 2-way
ANOVA followed by Bonferroni post hoc test. For within group comparison *p
<0.05, **p <0.01, ***p <0.001. p values indicate the level of differences between
Isolectin and AQP4 within each animal group. AQP4, aquaporin-4; BDL, bile
duct ligation. (This figure appears in colour on the web.)
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Research Article Cirrhosisshowed a trend towards lower vessel AQP4 expression in BDL
compared to sham-operated rats, though none of these changes
were statistically significant.
Evaluation of prefrontal cortex function: Spatial working
memory
To determine the possible functional consequences of altered
glymphatic flow and clearance, an array of behavioural and cog-
nitive tests was performed in BDL (n = 5) and sham-operated
(n = 5) animals. The prefrontal cortex is critically involved in
cognitive functions such as working memory, a process of main-
taining an active representation of information available for use,
as well as organisation and planning of responses.31 Testing
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Fig. 7. AQP4 polarisation and vessel coverage is not significantly lower in
the olfactory bulb and prefrontal cortex of animals with HE. (A) Summary
data illustrating AQP4 polarisation in the olfactory bulb and prefrontal cortex
of sham-operated and BDL animals, with no significant differences reported.
(B) Summary data illustrating AQP4 vessel coverage in the olfactory bulb and
prefrontal cortex of sham-operated and BDL animals, with no significant
differences reported. Statistical comparison was performed using 2-way
ANOVA followed by Bonferroni post hoc test. p values indicate the level of
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sham-operated (n = 5) and BDL (n = 5) rats. Summary data illustrating (B) rete
memory task, (D) speed of animal during the reference memory task, (E) distan
starting point to the escape box during the reference memory task comparin
operated and BDL animals were performed via 2-way ANOVA with Bonferroni p
way ANOVA was applied followed by Tukey post hoc test. p values indicate the
within group comparison *p <0.05, ***p <0.001. BDL, bile duct ligation.46 Journal of Hepatologyspatial working memory in the Barnes Maze was then used to
assess the function of prefrontal cortex. While there was no dif-
ference between the animal groups in time required to reach
the escape box during the sample trial (p = 0.3) (training on
the day to learn the new location of the escape box), significant
differences between the BDL and sham-operated animals in the
retention trial (p = 0.02) were recorded (Fig. 8A-B). These data
suggest that the BDL animals are unable to retain an active rep-
resentation of information, indicating impaired prefrontal cor-
tex function.
Evaluation of hippocampal function: Spatial reference
memory
As the hippocampus is important in the acquisition of spatial
reference memory32, further tests to assess its function were
performed in the Barnes Maze. Although no differences were
observed in escape latencies between BDL and sham-operated
animals (p = 0.2), the control group showed a progressive and
significant improvement in the task acquisition during the
training days (p = 0.01), which was not observed in the BDL ani-
mals (p > 0.05) (Fig. 8C). This indicates the inability of BDL ani-
mals to learn how to use the reference cues in order to reach the
escape box, suggesting potential impairment of hippocampal
function. There were no differences in the speed (p = 0.4) and
distance travelled (p = 0.4) between the two groups of animals,
suggesting that the observed differences in latency were not
due to the potential locomotor deficiency in the BDL rats (Fig. 8-BDL animals, was observed through the significant decrease in
distance covered (within the group, p <0.001), which was also
reflected in the increase of path efficiency (p = 0.01) along train-
ing days (Fig. 8F). These results demonstrate a functional mod-
ification to the observed alteration in glymphatic flow in the
hippocampus.
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Many diseases, mainly neurodegenerative, are associated with
accumulation of cellular waste products such as by-products
of metabolism and cellular respiration. Intracellular proteaso-
mal degradation and autophagy are considered the principal
means of removing proteins from the central nervous system
and the dysfunction of these processes has been associated with
neurodegeneration.33 Yet, many cytosolic proteins are released
into the interstitial space of the brain, suggesting that effective
disposal routes should exist to eliminate such waste. Data exist
showing the accumulation of many noxious substances and
metabolites in the ISF and CSF collected from the brain of
patients with HE,1 but the underlying mechanisms are not clear.
The data described herein, demonstrating an impairment of the
glymphatic system in BDL animals (Fig. 1), suggest that a lack of
clearance may contribute to the accumulation of noxious sub-
stances in the brains of patients with cirrhosis.
Using two lines of evidence; MRI and SF-ICP-MS, this study
demonstrates, for the first time, impaired CSF penetration and
parenchymal clearance of the contrast agent in frontal brain
regions (the olfactory bulb and prefrontal cortex) of BDL rats,
indicating a clear dysfunction of the glymphatic clearance sys-
tem in an animal model of chronic liver disease and HE. The rea-
sons underlying increased contrast agent inflow in the
hippocampus are currently unclear, but may be due to cell
loss/neurodegeneration, also seen in animal models of Alzhei-
mer’s disease or regional glial alterations that may occur in
HE.34 Cytotoxic oedema and energy depletion, which are known
features of HE, enhance glymphatic CSF influx while suppress-
ing ISF efflux,35 which may also contribute to the increased con-
trast inflow in the hippocampus. The data showing memory
deficits in this model of HE provide evidence of functional mod-
ifications, indicating impaired prefrontal cortex function as well
as potential derangement in hippocampal-prefrontal cortex
connections.
The pathophysiological mechanisms underlying impaired
glymphatic flow reported here are unclear. While we have
excluded the possibility of increased ICP and brain volume con-
tributing to this phenotype, our data suggest that significantly
lower AQP4 expression compared to the vasculature marker in
both the olfactory bulb and prefrontal cortex of BDL rats, could
contribute to the pathophysiological mechanisms underlying
the impaired glymphatic function. Furthermore, the moderately
altered AQP4 vessel coverage as well as polarisation could also
eventually contribute to altering glymphatic flow. This is an
important observation as other studies have proposed that
changes in AQP4 expression, localisation, or function may alter
glymphatic pathway function and contribute to the develop-
ment of Alzheimer’s disease or other neurodegenerative condi-
tions in animal models10 and in humans.22 Several other factors,
some known to be deranged in HE, such as reactive astroglio-
sis,36 hemichannel dysfunction,3 altered neuronal activity,35
arterial pulse-pressure,37 and central nervous system inflamma-
tion,38 may also play a role. Interestingly, many of these factors
are prominent in other diseases10 and could represent impor-
tant therapeutic targets to restore paravascular CSF-ISF
exchange.
Maintenance of volume homeostasis of cells requires energy.
Energy depletion can cause brain cell swelling termed cytotoxic
oedema.39 From extensive studies on HE rodent models, it is
known that ammonia plays a direct role in the development
of this astrocytic oedema,40 although this is mild in cirrhosisJournal of Hepatologyand associated HE. Astrocytic end-feet interpose a high-
resistance barrier to fluid-solute flux between paravascular
and interstitial compartments. Pericyte and microglial processes
are also scattered in between the vascular wall and astrocyte
end-feet, which creates a filter size of glial barrier large enough
for nearly all-mammalian proteins (35 kDa and diameter 2–
3 nm, including serum albumin 70 kDa and 4–6 nm diameter).
Astrocytic swelling (extending to end-feet) can therefore inter-
fere with the clearance of the brain by obstructing the paravas-
cular CSF-ISF exchange and solute clearance.
An interesting idea proposed by Thrane et al.,35 suggests that
gap-junction connections between astrocytes might rapidly dis-
tribute Na+-influx across the glial syncytium.41,42 Na+ and Cl
redistribution would in turn make ISF slightly hypo-osmolar rel-
ative to CSF,43 which would build an osmotic ISF-CSF gradient
that in theory would pull CSF into the ISF compartment. A study
from our group already demonstrated functional hemichannel
dysfunction in the cerebral cortex of BDL animals.3 This dys-
function could also extend to the gap-junction level, preventing
the distribution of these ions and therefore the development of
an osmotic gradient, which will consequently diminish the effi-
cacy of the glymphatic clearance pathway as demonstrated
here. This hypothesis will need to be tested in future studies.
In conclusion, this study provides the first experimental evi-
dence of impaired glymphatic inflow and clearance in a rodent
model of chronic liver disease and HE, with decreased expres-
sion of AQP4 suggested to play a mechanistic role.
Financial support
This study was supported by Grand Challenges UCL and The
Wellcome Trust (to Alexander V. Gourine). Alexander V. Gourine
is a Wellcome Trust Senior Research Fellow (Refs: 095064 and
200893). Mark F. Lythgoe receives funding from the EPSRC (EP/
N034864/1); the King’s College London and UCL Comprehensive
Cancer Imaging Centre CR-UK & EPSRC, in association with the
MRC and DoH (England); UK Regenerative Medicine Platform
Safety Hub (MRC: MR/K026739/1); Eli Lilly and Company.
Authors would like to thank, Ozama Ismail for his help with
the surgical preparation associated with the dynamic contrast-
enhanced MRI, Dr. Jack Wells for his assistance in setting up
the MRI protocol and Christina Elia for her help with figures.
Conflict of interest
Rajiv Jalan has research collaborations with Yaqrit and Takeda.
Rajiv Jalan is the inventor of OPA, which has been patented by
UCL and licensed to Mallinckrodt Pharma. He is also the founder
of Yaqrit limited, a spin out company from University College
London. All other authors report no conflict of interest.
Please refer to the accompanying ICMJE disclosure forms for
further details.
Authors’ contributions
Anna Hadjihambi and Ian F. Harrison: Performed and analysed
the MRI, Gd-DTPA intracerebral injections, ICP, immunofluores-
cence experiments. Wrote the paper and constructed the
figures. Marta Costas-Rodríguez and Frank Vanhaecke:
Performed elemental analysis (Gd-DTPA quantification) of
blood plasma, CSF and brain tissue samples using SF-ICP-MS
and contributed to writing the paper. Natalia Arias: Performed2019 vol. 70 j 40–49 47
[published Online First: 2014/09/06].
Research Article Cirrhosisand analysed behavioural experiments. Rocío Gallego-Durán:
Performed statistical comparisons and figures for behavioural
experiments. Svetlana Mastitskaya: Acquired immunofluores-
cence images with the confocal microscope. Patrick S. Hosford:
Assisted in writing the paper and data analysis. Steven W. M.
Olde Damink: Performed bile acid quantification experiments.
Nathan Davies and Abeba Habtesion: Performed bile duct liga-
tion surgery. Mark F. Lythgoe: Contributed funding to the study,
developed the MRI methods, and supervised research staff.
Alexander V. Gourine and Rajiv Jalan: Led and funded the study.
Supervised the manuscript and figure composition.
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.jhep.2018.08.021.
References
Author names in bold designate shared co-first authorship
[1] Weiss N, Barbier Saint Hilaire P, Colsch B, Isnard F, Attala S, Schaefer A,
et al. Cerebrospinal fluid metabolomics highlights dysregulation of
energy metabolism in overt hepatic encephalopathy. J Hepatol
2016;65:1120–1130. https://doi.org/10.1016/j.jhep.2016.07.046.
[2] Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the
neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis.
Hepatology 2010;51(3):1062–1069. https://doi.org/10.1002/hep.23367.
[3] Hadjihambi A, De Chiara F, Hosford PS, Habtetion A, Karagiannis A,
Davies N, et al. Ammonia mediates cortical hemichannel dysfunction in
rodent models of chronic liver disease. Hepatology 2017;65
(4):1306–1318. https://doi.org/10.1002/hep.29031.
[4] Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, et al. Brain-wide
pathway for waste clearance captured by contrast-enhanced MRI. J Clin
Invest 2013;123(3):1299–1309. https://doi.org/10.1172/JCI67677, [pub-
lished Online First: 2013/02/26].
[5] Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A
paravascular pathway facilitates CSF flow through the brain parenchyma
and the clearance of interstitial solutes, including amyloid beta. Sci
Transl Med 2012;4(147):147ra11. https://doi.org/10.1126/sci-
translmed.3003748, [published Online First: 2012/08/17].
[6] LouveauA,Smirnov I, KeyesTJ, Eccles JD,Rouhani SJ, Peske JD, et al. Structural
and functional features of central nervous system lymphatic vessels. Nature
2015;523(7560):337–341. https://doi.org/10.1038/nature14432.
[7] Bacyinski A, Xu M, Wang W, Hu J. The paravascular pathway for brain
waste clearance: current understanding, significance and controversy.
Front Neuroanat 2017;11:101. https://doi.org/10.3389/fna-
na.2017.00101, [published Online First: 2017/11/23].
[8] Nakada T, Kwee IL. Fluid dynamics inside the brain barrier: current
concept of interstitial flow, glymphatic flow, and cerebrospinal fluid
circulation in the brain. Neuroscientist 2018. https://doi.org/10.1177/
1073858418775027, [published Online First: 2018/05/26]
1073858418775027.
[9] Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG. The role of brain
barriers in fluid movement in the CNS: is there a ’glymphatic’ system?
Acta Neuropathol 2018;135(3):387–407. https://doi.org/10.1007/
s00401-018-1812-4, [published Online First: 2018/02/13].
[10] Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al.
Impairment of paravascular clearance pathways in the aging brain.
Ann Neurol 2014;76(6):845–861. https://doi.org/10.1002/ana.24271,
[published Online First: 2014/09/11].
[11] Lundgaard I, Lu ML, Yang E, Peng W, Mestre H, Hitomi E, et al.
Glymphatic clearance controls state-dependent changes in brain lactate
concentration. J Cereb Blood Flow Metab 2017;37(6):2112–2124.
https://doi.org/10.1177/0271678X16661202, [published Online First:
2016/08/03].
[12] Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, et al.
Glymphatic distribution of CSF-derived apoE into brain is isoform
specific and suppressed during sleep deprivation. Mol Neurodegener
2016;11(1):74. https://doi.org/10.1186/s13024-016-0138-8, [published
Online First: 2016/12/10].
48 Journal of Hepatology[13] Jiang Q, Zhang L, Ding G, Davoodi-Bojd E, Li Q, Li L, et al. Impairment of
the glymphatic system after diabetes. J Cereb Blood Flow Metab 2017;37
(4):1326–1337. https://doi.org/10.1177/0271678X16654702, [published
Online First: 2016/06/17].
[14] Plog BA, Nedergaard M. The glymphatic system in central nervous
system health and disease: past, present, and future. Annu Rev Pathol
2018;13:379–394. https://doi.org/10.1146/annurev-pathol-051217-
111018, [published Online First: 2017/12/02].
[15] Sullan MJ, Asken BM, Jaffee MS, DeKosky ST, Bauer RM. Glymphatic
system disruption as a mediator of brain trauma and chronic traumatic
encephalopathy. Neurosci Biobehav Rev 2018;84:316–324. https://doi.
org/10.1016/j.neubiorev.2017.08.016, [published Online First: 2017/09/
02].
[16] Peng WG, Achariyar TM, Li BM, Liao YH, Mestre H, Hitomi E, et al.
Suppression of glymphatic fluid transport in a mouse model of
Alzheimer’s disease. Neurobiol Dis 2016;93:215–225. https://doi.org/
10.1016/j.nbd.2016.05.015.
[17] Benveniste H, Lee H, Ding F, Sun Q, Al-Bizri E, Makaryus R, et al.
Anesthesia with dexmedetomidine and low-dose isoflurane increases
solute transport via the glymphatic pathway in rat brain when compared
with high-dose isoflurane. Anesthesiology 2017;127(6):976–988.
https://doi.org/10.1097/ALN.0000000000001888, [published Online
First: 2017/09/25].
[18] Gaberel T, Gakuba C, Goulay R, Martinez De Lizarrondo S, Hanouz JL,
Emery E, et al. Impaired glymphatic perfusion after strokes revealed by
contrast-enhanced MRI: a new target for fibrinolysis? Stroke 2014;45
(10):3092–3096. https://doi.org/10.1161/STROKEAHA.114.006617,[19] Gakuba C, Gaberel T, Goursaud S, Bourges J, Di Palma C, Quenault A, et al.
General anesthesia inhibits the activity of the ‘‘glymphatic system”.
Theranostics 2018;8(3):710–722. https://doi.org/10.7150/thno.19154,
[published Online First: 2018/01/19].
[20] Lee H, Mortensen K, Sanggaard S, Koch P, Brunner H, Quistorff B, et al.
Quantitative Gd-DOTA uptake from cerebrospinal fluid into rat brain
using 3D VFA-SPGR at 9.4 T. Magn Reson Med 2018;79(3):1568–1578.
https://doi.org/10.1002/mrm.26779, [published Online First: 2017/06/
20].
[21] Lee H, Xie L, Yu M, Kang H, Feng T, Deane R, et al. The effect of body
posture on brain glymphatic transport. J Neurosci 2015;35
(31):11034–11044. https://doi.org/10.1523/JNEUROSCI.1625-15.2015,
[published Online First: 2015/08/08].
[22] Eide PK, Ringstad G. MRI with intrathecal MRI gadolinium contrast
medium administration: a possible method to assess glymphatic func-
tion in human brain. Acta Radiol Open 2015;4(11). https://doi.org/
10.1177/2058460115609635, [published Online First: 2015/12/04]
2058460115609635.
[23] Eide PK, Ringstad G. Delayed clearance of cerebrospinal fluid tracer from
entorhinal cortex in idiopathic normal pressure hydrocephalus: a
glymphatic magnetic resonance imaging study. J Cereb Blood Flow
Metab 2018. https://doi.org/10.1177/0271678X18760974, [published
Online First: 2018/02/28] 271678X18760974.
[24] Eide PK, Vatnehol SAS, Emblem KE, Ringstad G. Magnetic resonance
imaging provides evidence of glymphatic drainage from human brain to
cervical lymph nodes. Sci Rep 2018;8(1):7194. https://doi.org/10.1038/
s41598-018-25666-4, [published Online First: 2018/05/10].
[25] Ringstad G, Valnes LM, Dale AM, Pripp AH, Vatnehol SS, Emblem KE, et al.
Brain-wide glymphatic enhancement and clearance in humans assessed
with MRI. JCI Insight 2018;3(13). https://doi.org/10.1172/jci.in-
sight.121537, [published Online First: 2018/07/13].
[26] Ringstad G, Vatnehol SAS, Eide PK. Glymphatic MRI in idiopathic normal
pressure hydrocephalus. Brain 2017;140(10):2691–2705. https://doi.
org/10.1093/brain/awx191, [published Online First: 2017/10/04].
[27] Harry D, Anand R, Holt S, Davies S, Marley R, Fernando B, et al. Increased
sensitivity to endotoxemia in the bile duct-ligated cirrhotic Rat. Hepa-
tology 1999;30(5):1198–1205. https://doi.org/10.1002/hep.510300515.
[28] Yang L, Kress BT, Weber HJ, Thiyagarajan M, Wang B, Deane R, et al.
Evaluating glymphatic pathway function utilizing clinically relevant
intrathecal infusion of CSF tracer. Journal of Translational Medicine
2013;11:107. https://doi.org/10.1186/1479-5876-11-107, [published
Online First: 2013/05/03].
[29] Peters BP, Goldstein IJ. The use of fluorescein-conjugated Bandeiraea
simplicifolia B4-isolectin as a histochemical reagent for the detection of
alpha-D-galactopyranosyl groups. Their occurrence in basement mem-
branes. Exp Cell Res 1979;120:321–334.
[30] Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using
G*Power 3.1: tests for correlation and regression analyses. Behav Res
2019 vol. 70 j 40–49
Methods 2009;41(4):1149–1160. https://doi.org/10.3758/
BRM.41.4.1149, [published Online First: 2009/11/10].
[31] Fuster JM. Behavioral electrophysiology of the prefrontal cortex of the
primate. Progr Brain Res 1990;85:313–323, discussion 23–24.
[32] Li L, Sase A, Patil S, Sunyer B, Hoger H, Smalla KH, et al. Distinct set of
kinases induced after retrieval of spatial memory discriminate memory
modulation processes in the mouse hippocampus. Hippocampus
2013;23(8):672–683. https://doi.org/10.1002/hipo.22127.
[33] Nedelsky NB, Todd PK, Taylor JP. Autophagy and the ubiquitin-protea-
some system: collaborators in neuroprotection. Biochim Biophys Acta
2008;1782(12):691–699. https://doi.org/10.1016/j.bbadis.2008.10.002,
[published Online First: 2008/10/22].
[34] Hernandez-Rabaza V, Cabrera-Pastor A, Taoro-Gonzalez L, Malaguarnera
M, Agusti A, Llansola M, et al. Hyperammonemia induces glial activation,
neuroinflammation and alters neurotransmitter receptors in hippocam-
pus, impairing spatial learning: reversal by sulforaphane. J Neuroin-
flamm 2016;13:41. https://doi.org/10.1186/s12974-016-0505-y,
[published Online First: 2016/02/18].
[35] Thrane AS, Rangroo Thrane V, Nedergaard M. Drowning stars: reassess-
ing the role of astrocytes in brain edema. Trends Neurosci 2014;37
(11):620–628. https://doi.org/10.1016/j.tins.2014.08.010.
[36] Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, et al.
Impairment of glymphatic pathway function promotes tau pathology
after traumatic brain injury. J Neurosci 2014;34(49):16180–16193.
https://doi.org/10.1523/JNEUROSCI.3020-14.2014, [published Online
First: 2014/12/05].
[37] Iliff JJ, Wang M, Zeppenfeld DM, Venkataraman A, Plog BA, Liao Y, et al.
Cerebral arterial pulsation drives paravascular CSF-interstitial fluid
exchange in the murine brain. J Neurosci 2013;33(46):18190–18199.
https://doi.org/10.1523/JNEUROSCI.1592-13.2013.
[38] Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA, Banks
WA. Lipopolysaccharide impairs amyloid beta efflux from brain: altered
vascular sequestration, cerebrospinal fluid reabsorption, peripheral
clearance and transporter function at the blood-brain barrier. J Neu-
roinflamm 2012;9:150. https://doi.org/10.1186/1742-2094-9-150.
[39] Thrane AS, Rappold PM, Fujita T, Torres A, Bekar LK, Takano T, et al.
Critical role of aquaporin-4 (AQP4) in astrocytic Ca2+ signaling events
elicited by cerebral edema. Proc Natl Acad Sci U S A 2011;108
(2):846–851. https://doi.org/10.1073/pnas.1015217108.
[40] Norenberg MD, Rao KV, Jayakumar AR. Mechanisms of ammonia-
induced astrocyte swelling. Metab Brain Dis 2005;20(4):303–318.
https://doi.org/10.1007/s11011-005-7911-7, [published Online First:
2005/12/31].
[41] Ezan P, Andre P, Cisternino S, Saubamea B, Boulay AC, Doutremer S,
et al. Deletion of astroglial connexins weakens the blood-brain barrier. J
Cereb Blood Flow Metab 2012;32(8):1457–1467. https://doi.org/
10.1038/jcbfm.2012.45, [published Online First: 2012/04/05].
[42] Rose CR, Ransom BR. Gap junctions equalize intracellular Na+ concen-
tration in astrocytes. Glia 1997;20(4):299–307, [published Online First:
1997/08/01].
[43] Ishimaru S, Okada Y, Mies G, Hossmann KA. Relationship between blood
flow and blood-brain barrier permeability of sodium and albumin in
focal ischaemia of rats: a triple tracer autoradiographic study. Acta
Neurochir 1993;120(1–2):72–80, [published Online First: 1993/01/01].
JOURNAL 
OF HEPATOLOGY
Journal of Hepatology 2019 vol. 70 j 40–49 49
